News Headlines Article

CMS policy change improved addiction treatment access
Modern Healthcare

The CMS’ push for Medicare plans to reduce preauthorization barriers to medication-assisted treatment for patients with opioid use disorders has worked very well, according to a new study.

Now the agency should apply similar pressure on Medicaid and private health plans, which cover a far larger number of Americans with addiction treatment needs, the researchers recommend in a study published in JAMA.

The CMS announced in April 2018 that it would not approve Medicare Part D formularies that required prior authorization for buprenorphine products more frequently than once a year.